logo
Reeves appears in public day after PMQs tears

Reeves appears in public day after PMQs tears

Yahoo5 days ago
Rachel Reeves has appeared in public with Sir Keir Starmer a day after breaking down in tears alongside the Prime Minister in the Commons.
The public show of unity came after Sir Keir gave her his full backing and said he did not appreciate how upset she was in the Commons because he was focused on answering Prime Minister's Questions.
The pair were both at the launch of the Government's 10-year plan for the NHS in London.
Ms Reeves was seen smiling and laughing with Sir Keir and Health Secretary Wes Streeting.
Setting out the Government's decision to pump cash into the NHS she said: 'We fixed the foundations and we've put our economy back on a strong footing.'
Earlier, the Prime Minister said all people could be caught 'off guard' by their emotions, but the Chancellor had to deal with it while on camera in Parliament.
He said she was doing an 'excellent' job, would remain in place beyond the next general election, and that they were both absolutely committed to the Chancellor's 'fiscal rules' to maintain discipline over the public finances.
UK Government bonds rallied and the pound steadied on Thursday, after reassurances from the Prime Minister about the Chancellor's future.
The sight of her in tears on Wednesday, and the £5 billion black hole in her public spending plans as a result of the welfare U-turn, had spooked the markets, triggering a sharp sell-off of bonds, with the yield seeing the sharpest increase since US president Donald Trump's tariff plans shook up financial markets in April.
Sir Keir told Virgin Radio he had spoken to the Chancellor on Wednesday evening and she was 'fine', and her tears were as a result of a 'purely personal' matter rather than the 'ups and downs of this week'.
Ms Reeves was visibly upset as she sat beside Sir Keir in the Commons on Wednesday, but he said: 'I actually personally didn't appreciate it was happening in the Chamber, because I came in, I've got questions being fired at me in PMQs, so I'm constantly up at the despatch box and down.
'I think we just need to be clear, it's a personal matter, and I'm not going to breach Rachel's privacy by going into what's a personal matter for her.'
He said that 'in politics, you're on show the whole time, there's no hiding place'.
Ms Reeves was a 'great colleague, she's a friend of mine and I'll be working with her for a very long time to come'.
'But like all human beings, we're also personal.
'There are moments that catch us off guard and if you're in front of a camera for large periods of your life, unfortunately, that could be caught on camera in a way, if it had been anybody else at work, it would have not really been noticed.'
The sight of the Chancellor in tears on the front bench and Sir Keir's initial lack of public support for her caused jitters about the Government's borrowing plans, as Ms Reeves' commitment to her rules to control spending are a key reassuring factor for the bond markets.
Sir Keir said: 'She is an excellent Chancellor, she will be Chancellor for a very long time to come, into the next election and beyond it.
'She and I are absolutely committed to our fiscal rules and the economic stability that is so important to this country, and that is the rock on which we build everything else.
'On that issue, Rachel and I are in lockstep, and have been for years.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery

Associated Press

timean hour ago

  • Associated Press

Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery

LONDON--(BUSINESS WIRE)--Jul 8, 2025-- Plexāā, a MedTech startup behind the award-winning BLOOM 43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM 43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent. 1 BLOOM 43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning ™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM 43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation ™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. 'I want to thank our team for the tremendous progress it has made to make this financing possible,' said Dr. Saahil Mehta, founder and CEO of Plexāā. 'Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning ™, and it energizes the team as we prepare to bring BLOOM 43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery.' Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, 'Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM 43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. 'Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed.' Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM 43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin 1^, Joseph M. Firriolo 1, Nolan S. Karp 2, Ara A. Salibian 1 View source version on CONTACT: Media Contacts: Sam Choinski Pazanga Health Communications [email protected] (860) 301-5058 [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA NEW YORK INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH CONSUMER APPS/APPLICATIONS SURGERY PROFESSIONAL SERVICES ONCOLOGY MEDICAL DEVICES SOFTWARE DATA ANALYTICS HEALTH TECHNOLOGY WOMEN DATA MANAGEMENT SOURCE: Plexāā Copyright Business Wire 2025. PUB: 07/08/2025 03:46 PM/DISC: 07/08/2025 03:46 PM

France's EDF to cut stake in Sizewell C as Macron lands in Britain
France's EDF to cut stake in Sizewell C as Macron lands in Britain

Yahoo

time2 hours ago

  • Yahoo

France's EDF to cut stake in Sizewell C as Macron lands in Britain

French state nuclear giant EDF is preparing to reduce its stake in Britain's Sizewell C project as Emmanuel Macron holds talks with Sir Keir Starmer about the project. EDF has been the UK Government's only partner on the £40bn scheme for the past three years, following the ejection of China General Nuclear (CGN) over security concerns. But in a fundraising round that is expected to bring in further investors including British Gas owner Centrica, EDF has confirmed that its share of the project will now fall. Bosses have decided to retain a stake of just 12.5pc, down from EDF's most recently declared level of 16.2pc, the Government said on Tuesday. This is at the lower end of a 10pc to 19.99pc range the company had previously suggested it would consider. However, it still represents a new £1.1bn investment and will be viewed as a boost to Sizewell's prospects following the UK Government's commitment to invest a further £14bn in the scheme last month. The investment was confirmed ahead of President Macron's meeting with the Prime Minister in Downing Street. Sir Keir said: 'I've been clear there will be no more dithering and delay on Sizewell C – and this investment takes us a step closer to the benefits it will bring to the British people. 'Lower energy bills, thousands more jobs and apprenticeships, and better energy security – this is not only a vote of confidence in the UK as an investment destination, it is our Plan for Change in action.' The reduced stake comes as EDF is under pressure at home to slash its exposure to foreign projects. It is grappling with huge cost and schedule overruns in the construction of the Hinkley Point C plant in Somerset. The company's share of Sizewell C, in Suffolk, has already been reduced passively by the UK Government's decision to pump further billions into preparatory work on-site. The latest development suggests EDF's management have opted to lower the company's exposure further rather than put more money in to maintain the current stake or increase its size. EDF's board was due to meet on Tuesday to confirm the move, Bloomberg reported. Other investors are expected to formally confirm their backing for Sizewell C when the UK Government takes a final investment decision in the coming weeks. Centrica is reportedly set to take a 15pc stake, with other potential investors including Amber Infrastructure Partners, Brookfield Asset Management and the Canadian pension fund CDPQ. Hinkley and Sizewell will each have two reactors, with both projects generating enough electricity to power about 6m homes. Cost overruns and delays at Hinkley have been blamed on skills shortages and regulatory hurdles, with the final cost expected to balloon to as much as £48bn in today's prices. Sizewell C's cost is expected to be lower, at around £41bn, thanks to shared designs and supply chains. Simone Rossi, chief executive of EDF's UK business, said: 'EDF's intention to invest in Sizewell C is a further sign of its commitment to investing in Britain's energy security and economic growth. 'It continues over 25 years of investment across the UK. EDF is proud to have restarted new nuclear in the UK, with Hinkley Point C paving the way for Sizewell C and constituting significant ongoing investment.' The company is currently spending £100m per week on Hinkley Point C. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store